ARVO: Latanoprost Halts Myopia Progression in Animal Study

Share this content:
ARVO: Latanoprost Halts Myopia Progression in Animal Study
ARVO: Latanoprost Halts Myopia Progression in Animal Study

FRIDAY, May 12, 2017 (HealthDay News) -- Daily topical latanoprost may help stop progression of myopia, offering a potential new treatment for the condition, according to an experimental study presented at the annual meeting of the Association for Research in Vision and Ophthalmology, held from May 7 to 11 in Baltimore.

Nevin El-Nimri, O.D., and Christine F. Wildsoet, O.D., Ph.D., from the University of California Berkeley, performed monocular form deprivation (FD) in young guinea pigs from age 14 days for 12 weeks. After the first week, FD eyes received daily topical latanoprost or vehicle (four each).

The researchers found that relative to vehicle treatment, latanoprost reduced intraocular pressure (IOP) and slowed myopia progression. There were changes in the mean interocular IOP differences from baseline values of −0.58 ± 0.94 mm Hg and −1.25 ± 1.1 mm Hg for vehicle and latanoprost to 0.56 ± 1.34 mm Hg and −7.11 ± 3.66 mm Hg, respectively. There were changes in the interocular optical axial length differences, from −0.01 ± 0.04 to 0.22 ± 0.13 mm Hg for vehicle and from −0.05 ± 0.06 to −0.01 ± 0.05 mm Hg for latanoprost. Compared with vehicle eyes, in latanoprost eyes the fluctuations in IOP appeared to be lower and less variable, although the difference was not significant.

"The results demonstrate that daily topical latanoprost is effective in both lowering IOP and slowing myopia progression in FD eyes of young guinea pigs," the authors write.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Actemra to Treat Giant Cell Arteritis

FDA Approves Actemra to Treat Giant Cell Arteritis

New indication provides the first FDA-approved therapy specific to this type of vasculitis

Trends in Teen Binge Drinking Still Raise Concerns

Trends in Teen Binge Drinking Still Raise Concerns

Even though frequent binge drinking among adolescents has dropped in past 25 years

ATS: First Abx Rx Doesn't Work for 25 of Pneumonia Cases

ATS: First Abx Rx Doesn't Work for ~25% ...

One in four adult patients do not respond to initial prescription of antibiotic treatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »